Lutera (LYT-100) is an emerging oral anti-inflammatory therapy currently being studied for its potential in treating chronic inflammatory conditions, including sinus-related disease. Though still under clinical investigation, its active compound, deupirfenidone, is designed to reduce tissue fibrosis and inflammation at the source.
At ENT New York, we stay at the forefront of medical innovation and are monitoring the development of therapies like Lutera closely. While it is not yet FDA-approved for routine ENT use, Dr. Kumra can discuss investigational treatments or clinical trial opportunities with eligible patients.
